We're sorry, but we're unable to process your login. Please try again.
We're sorry, you are not authorized to access this site. Please contact your local Merck representative if you have any inquiries.
This page requires you to register for an account with Merck. Please login with your Merck account credentials below, or register for a new account.

Log in with Merck
{* #signInForm *}
{* signInEmailAddress *}
{* currentPassword *}
{* captcha *}
{* /signInForm *}

Demonstrated efficacy

IN A 96-WEEK STUDY

MAVENCLAD DELIVERED SIGNIFICANT IMPROVEMENTS IN ARR, DISABILITY (EDSS) AND MRI ENDPOINTS VS.
PLACEBO1,2*

Measuring efficacy – the CLARITY study

CLARITY study design1

92% of MAVENCLAD patients (vs. 87% of the placebo group) completed the full 96-week study. 3.5% of MAVENCLAD patients discontinued the study due to AEs.1,2

§ The 5.25 mg/kg dosage regimen is not available.

¶ Combined unique lesions were defined as new GD+ T1-weighted lesions or new nonenhancing or enlarging T2-weighted lesions (without double-counting).  

Learn more about MAVENCLAD

 

Demonstrated reduction in ARR

 

Demonstrated reduction in 3-month EDSS progression

Demonstrated reduction in brain lesions

 

 

See how MAVENCLAD
achieved a 57.6% relative reduction in ARR over
96 weeks vs. placebo
(p<0.001, 0.14 vs. 0.33, respectively).

Learn more

See how MAVENCLAD delivered a 33%
reduction in risk of disability progression (EDSS) vs. placebo (p=0.02, HR: 0.67,
secondary endpoint).

Learn more


Discover how MAVENCLAD
demonstrated an 86% relative
reduction in T1 Gd+ lesions and
73% in T2 lesions over 96 weeks
vs. placebo (p<0.001; mean lesions:
T1 Gd+, 0.12 vs. 0.91; T2,  0.38 vs. 1.43; secondary endpoint). 

Learn more

 
Footnotes and References

ARR=annualized relapse rate; EDSS=Expanded Disability Status Scale; Gd+=gadolinium-enhancing; MRI=magnetic resonance imaging; RRMS=relapsing-remitting multiple sclerosis

* 96-week, phase III, multicentre, double-blind, placebo-controlled trial to evaluate the safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis. 1,326 patients were randomized (1:1:1) to receive a cumulative dose of cladribine tablets (3.5 mg/kg [n=433] or 5.25 mg/kg [n=456]) or placebo (n=437), in two treatment courses. The 5.25 mg/kg dosage regimen is not available.1

† 10th percentile of time to event.

  1. MAVENCLAD™ Product Monograph. EMD Serono. November 2017.
  2. Giovannoni G, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010;362:416-26.

You are leaving our website

You are now leaving our website. This link may lead to a resource maintained by third parties over whom we have no control. As such, we are not responsible for and make no representation to the accuracy or any other aspect of such resource or the privacy practices of such third party. Providing links to a third-party website does not constitute an endorsement by our company of such website or the information or products presented on such website.